- Bayer Group
- About Bayer
- Brand & Values
- Strategic Alignment
- Outlook and Targets
- Opportunity and Risk Report
- Corporate Governance
- Articles of Incorporation
- Board of Management
- Supervisory Board
- Sustainability and Commitment
- Listing and Key Figures
- Share Price
- Capital Increase
- Stockholders' Portal
- Ownership Structure
- Stock Programs
- Stock History
- Annual Stockholders’ Meeting 2019
- Live Events
- Stockholders' Meetings
- Inside Information
- Investor News
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
Bayer is a life science company and a global leader in health care and nutrition. Our innovative products support efforts to overcome the major challenges presented by a growing and aging global population. Guided by our corporate purpose “Bayer: Science for a better life,” we help to prevent, alleviate and treat diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials, while at the same time promoting the sustainable use of natural resources. Our business activities therefore also support the attainment of the United Nations Sustainable Development Goals.
We aim to bolster profitability and create value for our customers, shareholders and employees. Around the world, the Bayer brand stands for trust, reliability and quality. Across our various businesses, our activities are guided by our corporate values of Leadership, Integrity, Flexibility and Efficiency, or LIFE for short. Our value culture ensures a common identity throughout the enterprise across national boundaries, management hierarchies and cultural differences.
Published on February 27, 2019 in the Annual Report 2018:
|Key Data Bayer Group||2017||2018|
|€ million||€ million|
|EBITDA before special items1||9,288||9,547|
|EBITDA margin before special items (in %)1||26.5%||24.1%|
|EBIT before special items1||7,130||6,480|
|Income before income taxes||4,577||2,318|
|Net income (from continuing and discontinued operations)||7,336||1,695|
|Earnings per share (from continuing and discontinued operations) (€)1||8.29||1.80|
|Core earnings per share (from continuing operations) (€)1||6.64||5.94|
|Net cash provided by operating activities (from continuing and discontinued operations)||8,134||7,917|
|Net financial debt||3,595||35,679|
|Capital expenditures (as per segment table)2||2,418||2,564|
|Total dividend payment||2,402||2,611|
|Dividend per share (€)||2.80||2.80|
|Research and development expenses (€ million)||4,504||5,246|
|Ratio of R&D expenses to sales – Pharmaceuticals (%)||16.2||15.5|
|Ratio of R&D expenses to sales – Crop Science (%)||11.7||13.0|
|Employees in research and development3||14,041||17,275|
|Number of employees3 (Dec. 31)||99,820||116,998|
|Personnel expenses (including pension expenses) (€ million)||9,528||11,548|
|Proportion of employees with health insurance (%)||98||98|
|Fluctuation (voluntary / total) (%)||4.8 / 10.4||5.4 / 14.4|
|Hours of vocational and ongoing training per employee||23.4||17.1|
2017 figures restated; t = metric tons
1 For definitions of the indicators see Annual Report 2018, Chapter "Alternative Performance Measures Used by the Bayer Group"
2 Group total 2016 including Covestro
3 Employees calculated as full-time equivalents (FTEs)
4 RIR: Number of reportable occupational injuries and illnesses per 200,000 hours worked
5 LoPC = Loss of Primary Containment; number of incidents in which chemicals leak from their primary container, such as pipelines, pumps, tanks or drums, per 200,000 working hours
6 Quotient of total energy consumption and external sales
7 Direct emissions from power plants, waste incinerators and production plants and indirect emissions from external supplies of electricity, steam and refrigeration (according to the market-based method)
Current Investor News
The capital stock of Bayer AG, amounting to Euro 2,515,005,649.92 is divided into 982,424,082 no-par registered shares. The capital stock underlying the no-par value registered shares is evidenced by permanent global certificates deposited with Clearstream Banking AG, Frankfurt am Main, Germany. The Company’s shareholders have ownership in these certificates in proportion to their respective holdings.The current value of one share - the share price - is determined by the company's total value on the stock market (market capitalization) and the number of shares in circulation.
|Security Identification No.|
|Bloomberg||Xetra ®||BAYN GY|
|Frankfurter Wertpapierbörse||BAYN GF|
Bayer has a significant weighting in virtually all the major stock indices in line with its high market capitalization and share turnover.
Bayer stock is listed on all the German stock exchanges.
Paying and exchange agent for the shares of Bayer AG is Deutsche Bank AG (Taunusanlage 12, 60325 Frankfurt am Main, Germany).
Information about the dividend for fiscal 2018
The Annual Stockholders’ Meeting on April 26, 2019 resolved to use the distributable profit of EUR 2,611,145,499.20 for the fiscal year 2018 to pay a dividend of EUR 2.80 per share on the 932,551,964 no-par shares entitled to the dividend. The dividend yield calculated on the share price at year end 2018 amounts to 4.6 percent.
Stock ownership by region
Our ownership structure shows the international distribution of our capital stock. The highest proportion of our outstanding shares, approx. 30 percent, is held by investors in the United States and Canada, followed by Germany with approx. 20 percent. From a regional perspective, Bayer has a stable ownership structure that has altered only slightly in recent years.
Ownership Structure by Country
Taking the acquisition of Monsanto into account, the rating agencies have confirmed the following ratings:
|Rating agency||Long-term rating||Short-term rating||Outlook|
|S&P Global Ratings||BBB||A2||stable|
(published on October 30, 2019 in the Quarterly Statement Q3 2019)
Based on the business development described in this report and our internal planning, we confirm the Group outlook for fiscal 2019 published in February in our Annual Report 2018 despite falling growth expectations worldwide.
This original forecast was issued on the basis of all businesses being continuing operations. The envisaged portfolio measures (in particular the sale of Animal Health and Currenta) were not taken into account at that time since the timing of the divestments was not yet sufficiently certain. However, the progress we have since made on implementing these portfolio measures necessitates adjusting the original forecast to exclude the sales and earnings contributions from the discontinued operations Animal Health and the Currenta Group. The need for these adjustments arises solely from a change in presentation in the financial statements. The table below shows the original forecast alongside the adjusted forecast, which excludes the business entities now reported as discontinued operations.
Bayer Group Key Financial Data – Forecast for 2019
Original 2019 forecast1
2019 forecast adjusted to exclude discontinued operations (Animal Health & Currenta)
|Group sales||Increase of approx. 4%2||Increase of approx. 4%2|
|Approx. €46 billion||Approx. €43 billion|
|EBITDA before special items||Approx. €12.2 billion||Approx. €11.6 billion|
|Core earnings per share||Approx. €6.80||Approx. €6.45|
1 Issued in February 2019; including Animal Health and Currenta
2 Currency- and portfolio-adjusted
To enhance comparability, we issue our forecast on a currency-adjusted basis. Based on current exchange rates, we anticipate Group sales of approximately €43.5 billion, EBITDA before special items of approximately €11.5 billion, and core earnings per share of €6.35.
(published on February 27, 2019 in the Annual Report 2018)
The following forecast is based on the current business development and our internal planning.
To enhance the comparability of operating performance, the forecasts are adjusted for currency effects5. We do not anticipate any material changes in our forecast if the closing rates as of December 31, 2018, are used as a basis. A 1% appreciation (depreciation) of the euro against all other currencies would decrease (increase) sales on an annual basis by some €340 million and EBITDA before special items by about €100 million.
5 The average monthly exchange rates from 2018 (see Annual Report 2018, table “Exchange Rates for Major Currencies” in Note “Basic principles, methods and critical accounting estimates” ) were applied.
We confirm the forecasts for 2019 and the medium-term targets for 2022 that we provided in conjunction with our Capital Markets Day on December 5, 2018. For 2019, we expect sales to amount to around €46 billion. This corresponds to an increase of approximately 4% on a currency- and portfolio-adjusted basis. We aim to increase EBITDA before special items to approximately €12.2 billion on a currency-adjusted basis, while core earnings per share are seen rising to approximately €6.80 on a currency-adjusted basis.
Bayer Group Key Data – Forecast for 2019
|2018 figures||2019 forecast|
|€ billion||Fx & p adj. Change (%)||€ billion|| |
Fx & p adj. Change (%)
|Margin (%)||Margin (%)|
|EBITDA before special items1||9.5||24.1||~12.2||~27|
|Financial result (core)2||(1.3)||~(1.8)|
|Tax rate (core)3||20.6 %||~ 23%|
|Free cash flow1||4.7||~3 – 4|
|Net financial debt1,4||35.7||~36|
Fx & p adj. = currency- and portfolio-adjusted
1 For definition see Chapter “Alternative Performance Measures Used by the Bayer Group.”
2 Financial result before special items
3 (Income taxes + special items in income taxes + tax effects on adjustments) / (core EBIT + financial result + special items in financial result)
4 For 2019, including a lease liability of approximately €1.1 billion under IFRS 16
We expect substantial special charges in 2019, mainly in connection with restructuring measures.
The first-time application of IFRS 16 is expected to result in an around €0.3 billion increase in EBITDA before special items compared with the previous year. We also anticipate that free cash flow will rise by approximately €0.3 billion and net financial debt by approximately €1.1 billion due to this effect.
This fact sheet may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer Investor Relations
Dr. Jürgen Beunink